Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

NCT03516812 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Castration-Resistant Prostate Carcinoma
Prostate Adenocarcinoma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Olaparib
OTHER: Quality-of-Life Assessment
OTHER: Survey Administration
DRUG: Testosterone Enanthate
DRUG: Testosterone Cypionate

Sponsor

University of Washington

Collaborators

[object Object]
[object Object]